Angelini Pharma S.p.a.

The number of venture capital mega-rounds raised by biopharmaceutical companies has settled into a steady pace of six $100m-plus financings per month, with May matching the number of supersized VC rou

Angelini Pharma of Italy, which is hoping to become the leading brain health drugmaker in the sector, is buying a stake in GRIN Therapeutics and securing the international rights to the US biotech’s n

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Quiver, QurAlis To Combine Tech Platfor

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Angelini Licenses Cureverse’s Nov